AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11679441
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline infusion
Trial: 12135033
Drug: Tapering course
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering course of vancomycin
Trial: 12135033
Drug: Pulsed dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dosing of vancomycin
Trial: 12135033
Drug: High-dose vancomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vancomycin (> or =2 g/day)
Trial: 12135033
Drug: Low-dose metronidazole
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose metronidazole (< or =1 g/day)
Trial: 2679473
Drug: Hourly doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly doses of clonidine hydrochloride followed by maintenance therapy (group 1)
Trial: 2679473
Drug: An initial
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial dose of clonidine followed by hourly placebo and subsequent maintenance therapy (group 2)
Trial: 2679473
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy without prior loading (group 3)
Trial: 28642008
Drug: Twice-daily concurrent
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily concurrent chemoradiotherapy (45 Gy in 30 fractions of 1.5 Gy over 19 days)
Trial: 28642008
Drug: Twice-daily concurrent
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily concurrent chemoradiotherapy
Trial: 25934525
Drug: Sitagliptin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (25 mg titrated up to 50 mg)
Trial: 25934525
Drug: Glimepiride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (0.5 mg titrated up to 1 mg)
Trial: 15486607
Drug: Sertraline or
RxNorm normalized name: sertraline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline or Fluoxetine
Trial: 22446490
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg)
Trial: 8371822
Drug: Ranitidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (2 dd 150 mg) for 2 weeks
Trial: 31292181
Drug: Disease activity‐guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease activity‐guided tapering of biological disease-modifying antirheumatic drugs (bDMARDs)
Trial: 17234041
Drug: Psychosocial interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychosocial interventions with psychopharmacology as an adjunct
Trial: 17234041
Drug: Psychotropic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medication with psychosocial methods as an occasional adjunct
Trial: 14760258
Drug: Live quadrivalent
RxNorm normalized name: influenza virus vaccine, live quadrivalent nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live quadrivalent rotavirus vaccine (QRV)
Trial: 31567887
Drug: Split-dose PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose PEG (4000 mL/1.73 m PEG solution, half the dose day before and half on the day of colonoscopy)
Trial: 31567887
Drug: Single-dose PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose PEG (4000 mL/1.73 m PEG solution day before colonoscopy)
Trial: 26216729
Drug: Cytotoxic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic therapy plus placebo
Trial: 20961574
Drug: Enuresis alarm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enuresis alarm (as second line treatment)
Trial: 20961574
Drug: Desmopressin (as
RxNorm normalized name: Desmopressin (as desmopressin acetate) 25 microgram oral lyophilisate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (as second line treatment)
Trial: 28917383
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg ixekizumab every 2 weeks for weeks 0-12, then every 4 weeks during LTE
Trial: 17942835
Drug: Regular stimulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular stimulant use
Trial: 15801581
Drug: Interest in
RxNorm normalized name: CATH,INTERMIT,14FR MENTOR #3814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interest in nicotine replacement therapy (NRT)
Trial: 11764874
Drug: TCP-coated AML
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCP-coated AML femoral implant
Trial: 11764874
Drug: Standard AML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard AML femoral implant (control group)
Trial: 3318089
Drug: BCG or
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG or ADR (in cases of treatment failure)
Trial: 20973324
Drug: Ice applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice applied 5 minutes before injection
Trial: 20973324
Drug: Ice applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice applied 5 minutes after injection
Trial: 16187176
Drug: Therapy (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy (standard treatment for HCV)
Trial: 12537187
Drug: Retrograde autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrograde autologous priming (RAP) (395 +/- 150 mL)
Trial: 10768524
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for aphasia
Trial: 1500630
Drug: Peanut immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut immunotherapy
Trial: 31881986
Drug: Fortified bread
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified bread with 500 IU/100 g
Trial: 31881986
Drug: Fortified bread
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified bread with 1000 IU/100 g
Trial: 26764332
Drug: Aged Garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged Garlic Extract (AGE) 2.56 g/d for 90 days
Trial: 16237776
Drug: Perioperative parenteral
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative parenteral nutrition
Trial: 16237776
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no parenteral nutrition)
Trial: 12401582
Drug: 1.5 micro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 micro g/kg IV fentanyl
Trial: 12401582
Drug: 1.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% lidocaine plus 0.35 mg/kg IV propofol
Trial: 6809796
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy in an individual format
Trial: 26814246
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (0.375% ropivacaine, perineural additives)
Trial: 26814246
Drug: Medium Dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Dose (0.2% ropivacaine, perineural additives)
Trial: 26814246
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (0.1% ropivacaine, perineural additives)
Trial: 26814246
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose
Trial: 19057896
Drug: 25% nitrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% nitrous oxide inhalation
Trial: 16860171
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d for 20 days (group C, n=14)
Trial: 1352246
Drug: ipsapirone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipsapirone 10 mg
Trial: 8840346
Drug: ipsapirone 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipsapirone 20 mg
Trial: 6547988
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg cimetidine daily
Trial: 6547988
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg pirenzepine daily
Trial: 6547988
Drug: Control (pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pre-treatment levels)
Trial: 30930051
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training performed twice a week for 10 weeks
Trial: 18434976
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (200 microg once daily)
Trial: 21905959
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray
Trial: 13678869
Drug: Candesartan (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (target dose 32 mg once daily)
Trial: 6221388
Drug: Cefoperazone (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone (16 micrograms/ml)
Trial: 6221388
Drug: Cefamandole (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (16 micrograms/ml) and/or Tobramycin (4 micrograms/ml)
Trial: 31277180
Drug: M-DEPTH (evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-DEPTH (evidence-based stepped care treatment model)
Trial: 29216730
Drug: Therapy aimed
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy aimed at cervical muscles only
Trial: 29216730
Drug: Complex rehabilitation
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex rehabilitation (combination of relaxing and stretching exercises of cervical muscles with standard therapy for masticatory muscles)
Trial: 25738784
Drug: Balanced protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced protein intake (BAL: 25% daily protein/meal × 4)
Trial: 25738784
Drug: Skewed protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skewed protein intake (SKEW: 7:17:72:4% daily protein/meal)
Trial: 15231376
Drug: alpha-tocopherol 50
RxNorm normalized name: (+)-alpha-tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-tocopherol 50 mg
Trial: 15231376
Drug: beta-carotene 20
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-carotene 20 mg
Trial: 11199705
Drug: Nd:YAP laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAP laser with an energy of 240 mJ, a pulse repetition rate of 10 Hz (with water spray)
Trial: 11199705
Drug: High-speed dental
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-speed dental handpiece (with water spray)
Trial: 9049526
Drug: Quinaprilat (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinaprilat (5 ml or 10 ml injection twice daily)
Trial: 21067273
Drug: Group LS:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group LS: 20 mL of 0.25% levobupivacaine infiltration to the nephrostomy tract followed by intravenous saline infusion
Trial: 17300593
Drug: Vildagliptin 100
RxNorm normalized name: vildagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 100 mg q.d. + Pioglitazone 30 mg q.d. (50/15 mg q.d.)
Trial: 17300593
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg q.d. (monotherapy)
Trial: 11149474
Drug: Oral 10
RxNorm normalized name: Syringe Oral 10cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 10 mg alendronate
Trial: 10401948
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) in low ventilation group (10 l/min)
Trial: 8583073
Drug: Omeprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (80 mg bolus and 40 mg/12 h i.v.)
Trial: 8583073
Drug: Ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (50 mg/4 h i.v.)
Trial: 2193242
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (Sandoglobulin, Sandoz) 400 mg/kg, two times with an interval of two weeks
Trial: 31833543
Drug: IVCS +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVCS + Antibiotics (amoxicillin, vancomycin, metronidazole, doxycycline/ciprofloxacin)
Trial: 31833543
Drug: IVCS +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVCS + Antibiotics
Trial: 28492920
Drug: Intravitreous 0.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreous 0.5-mg ranibizumab therapy
Trial: 25929985
Drug: Optimized usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized usual primary care PTSD Treatment (OUC)
Trial: 8789548
Drug: Milk perfusion
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk perfusion (10 mL at 3 mL/min) in patients with cow's milk intolerance
Trial: 1362031
Drug: HM175 vaccine
RxNorm normalized name: hepatitis A vaccine (inactivated) strain HM175 Injection [Havrix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM175 vaccine (third dose)
Trial: 6528959
Drug: Uniphylline, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphylline, 600 mg once daily
Trial: 6367749
Drug: usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual treatment
Trial: 27026689
Drug: Intensive DMARD
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive DMARD therapy
Trial: 27026689
Drug: Standard DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard DMARD therapy
Trial: 23999998
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral cholecalciferol supplementation (140,000 IU/month)
Trial: 11002232
Drug: RT-CHOP (radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT-CHOP (radiotherapy followed by six cycles of CHOP chemotherapy)
Trial: 21851906
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg
Trial: 31593830
Drug: Matched molecularly
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matched molecularly targeted agents (MTAs) classified into ESCAT tiers II, IIIA, IIIB, and IVA
Trial: 27735021
Drug: Alprostadil 60
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil 60 mg and α-lipoic acid 600 mg in 250 mL normal saline, intravenous drip once per day for 2 weeks
Trial: 27735021
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg orally, once per night for 2 weeks
Trial: 20521272
Drug: GTFT 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTFT 1.4 g/L
Trial: 9001836
Drug: Mibefradil (6.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil (6.25, 12.5, 25, 50, or 100 mg/d)
Trial: 1291697
Drug: Group behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group behavioral therapy
Trial: 1291697
Drug: Cognitive-behavioral marital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral marital treatments
Trial: 2951089
Drug: Human ultralente
RxNorm normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human ultralente insulin (6 U)
Trial: 2951089
Drug: Bovine ultralente
RxNorm normalized name: INSULIN,ULTRALENTE,HUMAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine ultralente insulin
Trial: 30309276
Drug: Monthly health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly health coaching
Trial: 20485203
Drug: BUD 400
RxNorm normalized name: Clove buds
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD 400 microg twice daily for 1 month, then 200 microg twice daily for 5 months
Trial: 20485203
Drug: BUD 100
RxNorm normalized name: Clove buds
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD 100 microg twice daily
Trial: 10936668
Drug: Acarbose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (100 mg three times daily)
Trial: 7590814
Drug: cA2 chimeric
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cA2 chimeric anti-TNF alpha antibody (1 mg/kg)
Trial: 7590814
Drug: cA2 chimeric
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cA2 chimeric anti-TNF alpha antibody (10 mg/kg)
Trial: 367480
Drug: Cyproheptadine without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine without behaviour therapy
Trial: 367480
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with behaviour therapy
Trial: 367480
Drug: Placebo without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without behaviour therapy
Trial: 27365521
Drug: Control (brushing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (brushing teeth and gargling with 0.9% sodium chloride solution or water)
Trial: 30923036
Drug: Nivolumab/ipilimumab combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab/ipilimumab combination therapy
Trial: 21546160
Drug: S(+)‐ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine infusion (100-hour continuous intravenous infusion at 10-20mg/h)
Trial: 12691925
Drug: Topical NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical NSAIDs
Trial: 9067299
Drug: Nalbuphine 10
RxNorm normalized name: nalbuphine 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 10 mg/70 kg
Trial: 29097640
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (IPT‐SP) alone
Trial: 24224515
Drug: Intranasal DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal DEX 2 μg·kg(‐1) (group D2)
Trial: 22128226
Drug: Sildenafil (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (combined low-, medium-, high-dose)
Trial: 24637559
Drug: Medium-dose sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose sildenafil
Trial: 19243716
Drug: High-dose varenicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose varenicline (1 mg BID)
Trial: 19243716
Drug: Low-dose varenicline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose varenicline (0.5 mg BID)
Trial: 19243716
Drug: Low-dose varenicline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose varenicline (0.5 mg once daily)
Trial: 19243716
Drug: High-dose varenicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose varenicline (for low-body-weight group)
Trial: 17559730
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% film-forming solution (FFS)
Trial: 17559730
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% cream (Lamisil)
Trial: 9192123
Drug: Atenolol (25-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (25-100 mg)
Trial: 6417728
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no drugs)
Trial: 1327634
Drug: L-alanine infusion
RxNorm normalized name: L-alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-alanine infusion (0.70, 1.40, or 2.80 nmol/kg body weight over 4.5 min)
Trial: 1327634
Drug: L-alanine infusion
RxNorm normalized name: L-alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-alanine infusion (11.2 mmol/kg body weight in male Wistar rats)
Trial: 28939374
Drug: Intravenous corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous corticosteroids
Trial: 7631609
Drug: Warfarin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (n = 32)
Trial: 7631609
Drug: Warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin and Placebo
Trial: 6107987
Drug: Somatostatin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (600 pg/ml) added to distending fluid during 3 test periods in 10 subjects
Trial: 31464617
Drug: Wuzi Yanzong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuzi Yanzong pill